Fusen Pharmaceutical Reports Steep Mid-Year Losses

Fusen Pharmaceutical Co., Ltd. (HK:1652) has released an update.

Fusen Pharmaceutical Co., Ltd. has reported a significant downturn in its interim financial results for the first half of 2024, with revenues falling by 41.6% and gross profits down by 40.9% compared to the same period last year. The company also shifted from a profit of RMB 16.5 million in the first half of 2023 to a loss of RMB 36.9 million in the first half of 2024. This stark reversal highlights challenges faced by Fusen Pharmaceutical, potentially impacting investor confidence.

For further insights into HK:1652 stock, check out TipRanks’ Stock Analysis page.